Single-Dose Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections
- 591 Downloads
Intravenous dalbavancin (Dalvance®, Xydalba®), first approved as a two-dose regimen for the treatment of acute bacterial skin and skin structure infections (ABSSSI), has now been additionally approved as a single-dose regimen. This narrative review discusses the pharmacological properties of intravenous dalbavancin and its clinical efficacy and tolerability as a single-dose regimen in the treatment of adult patients with ABSSSI. Single-dose dalbavancin is an effective and generally well tolerated treatment option for adults with ABSSSI, with noninferior efficacy to the two-dose dalbavancin regimen with regard to early clinical response (at 48–72 h) and low rates of adverse events. Clinical success rates at days 14 and 28 also did not significantly differ between the single- and two-dose dalbavancin regimens; neither did clinical success rates at day 14 when analysed by baseline pathogen. It has a broad spectrum of activity against common ABSSSI-related pathogens, and a favourable pharmacokinetic profile allowing for the convenience of single-dose administration. Thus, dalbavancin presents a promising alternative to conventional antibacterials for the treatment of ABSSSI in adult patients.
KeywordsVancomycin Linezolid Daptomycin Clinical Success Rate Moderate Renal Impairment
During the peer review process, the manufacturer of dalbavancin was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflicts of interest
Karly P. Garnock-Jones is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.
- 4.Durata Therapeutics US Ltd. Dalvance® (dalbavancin for injection, for intravenous use): US prescribing information. 2016. http://www.allergan.com. Accessed 11 Nov 2016.
- 5.European Medicines Agency. Xydalba® (dalbavancin powder for concentrate for solution for infusion): EU summary of product characteristics. 2016. http://www.ema.europa.eu. Accessed 11 Nov 2016.
- 10.The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 6.0, 2016. 2016. http://www.eucast.org/clinical_breakpoints/. Accessed 11 Nov 2016.
- 12.Lopez S, Hackbarth C, Romano G, et al. In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide. J Antimicrob Chemother. 2005;55(Suppl 2):ii21–4.Google Scholar
- 20.Huband MD, Castanheira M, Farrell DJ, et al. In vitro activity of dalbavancin against multidrug-resistant Staphylococcus aureus and streptococci from patients with documented infections in Europe and surrounding regions (2011–2013). Int J Antimicrob Agents. 2016;47(6):495–9.CrossRefPubMedGoogle Scholar
- 23.Dunne M, Boucher H, Wilcox MH, et al. Microbiologic analysis of target pathogens identified in the dalbavancin DISCOVER program [abstract no. 1338]. In: Infectious Diseases Week. 2013.Google Scholar
- 26.Koeth LM, DiFranco-Fisher JM, Dunne M, et al. Dalbavancin and azithromycin synergy/antagonism study by checkerboard MIC [abstract no. D-877]. In: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy. 2014.Google Scholar
- 29.Bhavnani SM, Hammel JP, Rubino CM, et al. Pharmacokinetic–pharmacodynamic (PK–PD) analyses for the efficacy of dalbavancin (DAL) using phase 3 data from patients with acute bacterial skin and skin structure infections (ABSSSI) [abstract no. A-1186]. In: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy. 2014.Google Scholar
- 33.Data on file, Allergan, 2015.Google Scholar
- 37.The Medicines Company. Orbactiv® (oritavancin for injection, for intravenous use): US prescribing information. 2016. http://www.themedicinescompany.com. Accessed 29 Aug 2016.
- 38.European Medicines Agency. Orbactiv® (oritavancin 400 mg powder for concentrate for solution for infusion): EU summary of product characteristics. 2016. http://www.ema.europa.eu. Accessed 29 Aug 2016.
- 39.European Medicines Agency. EMA assessment report for Xydalba® (dalbavancin powder for concentrate for solution for infusion). EMA/39820/2015. 2015. http://www.ema.europa.eu. Accessed 2 Nov 2016.